Digoxin (NSC 95100)

Catalog No.S4290

For research use only.

Digoxin (NSC 95100) is a classical Na,K-ATPase inhibitor, with selectivity for the α2β3 isoform over the common α1β1 isoform, used in the treatment of atrial fibrillation and heart failure.

Digoxin (NSC 95100) Chemical Structure

CAS No. 20830-75-5

Selleck's Digoxin (NSC 95100) has been cited by 6 Publications

Purity & Quality Control

Choose Selective ATPase Inhibitors

Other ATPase Products

Biological Activity

Description Digoxin (NSC 95100) is a classical Na,K-ATPase inhibitor, with selectivity for the α2β3 isoform over the common α1β1 isoform, used in the treatment of atrial fibrillation and heart failure.
Targets
Na,K-ATPase α2β3 [1]
()
Na,K-ATPase α2β1 [1]
()
Na,K-ATPase α1β1 [1]
()
42.8 nM(Ki) 58.7 nM(Ki) 268 nM(Ki)
Cell Data
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID
rat hepatocytes MUHGeY5kfGmxbjDhd5NigQ>? MXfEdpVoKHWydHHr[UBqdiC{YYSgbIVx[XSxY4n0[ZMtKEuvPUCuNVgh|ryP NFnyeFY9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{MEmyOlYyQSd-MkC5NlY3OTl:L3G+
human hepatocytes NIrJeZpHfW6ldHnvckBie3OjeR?= NVSwfGhXOC5yNTD0c{AyOCC3TR?= M2X2O2RzfWdidYD0ZYtmKGmwIIPhcoR4cWOqLXP1cJR2emWmIHj1cYFvKGincHH0c4N6fGW|IHH0JFAvODVidH:gNVAhfU1iYYSgN|ch\GWpQzDifUBOcWOqYXXsbZMuVWWwdHXuJItqdmW2aXPzM5NkcW62aXzsZZRqd25ic4DlZ5Rzd3Olb4D5MEBMdT1{LkO5JO69VQ>? M4S3[VxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJyOUK2OlE6Lz5{MEmyOlYyQTxxYU6=
LLC-PK1 MVfGeY5kfGmxbjDhd5NigQ>? M1TnV3RRZ1SUQV7TVG9TXEWUOjDpcohq[mm2aX;uJI9nKEV{MUfi[ZRiTyC3cIThb4UhcW5iT3H0dFIu\XiycnXzd4lv\yCOTFOtVGsyKGOnbHzzMEBMcT1yLkCzO:69VQ>? MX[8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8yOTRyOEW1O{c,OTF2MEi1OVc9N2F-
High Five (BTI-TN5B1-4) NEXabZRHfW6ldHnvckBie3OjeR?= NWS3e5ViXFChVGLBUnNRV1KWRWK6JGFVWCCqeXTyc4x6e2m|IHnuJI1mdWK{YX7lJIZz[WO2aX;uJIZzd21iSHnnbEBHcX[nIDjCWGkuXE53QkGtOEkh[2WubIOsJGtuRTJ3LkpOwG0> MmW2QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOTF5OEW2PFQoRjFzN{i1Olg1RC:jPh?=
LLC-PK1 MlWwSpVv[3Srb36gZZN{[Xl? MWfUVH9VWkGQU2DPVnRGWjpiaX7obYJqfGmxbjDv[kBV[XW{b3Poc4xifGVidYD0ZYtmKGmwIF;heJAzNWW6cILld5NqdmdiTFzDMXBMOSClZXzsd{whU2l;MD61PO69VQ>? NWXlZmQ{RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMUG3PVI3QTRpPkGxO|kzPjl2PD;hQi=>
LLC-PK1 Ml;YSpVv[3Srb36gZZN{[Xl? NW\vRW5RXFChVGLBUnNRV1KWRWK6JJVxfGGtZTDpckBQ[XSyMj3lfJBz\XO|aX7nJGxNSy2SS{GgZ4VtdHNuIFvtQVEvODgQvF2= MUW8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8yOTd7Mk[5OEc,OTF5OUK2PVQ9N2F-
LLC-PK1 NGjRc|dHfW6ldHnvckBie3OjeR?= NUnKcYF7XFChVGLBUnNRV1KWRWK6JJVxfGGtZTDpckBQ[XSyMj3lfJBz\XO|aX7nJGxNSy2SS{GgZ4VtdHNuIFvtQVAvOjd7zszN MVW8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8yOTh6M{[0NUc,OTF6OEO2OFE9N2F-
MDCK MljBSpVv[3Srb36gZZN{[Xl? M3;uTXRRZ1SUQV7TVG9TXEWUOjDj[YxtKGGlY4XteYxifGmxbjDpckBQSVSSNFOxMYV5eHKnc4PpcochVUSFSzDj[YxteyxiS329O{45|ryP MX28ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8yPDl7M{[wOEc,OTR7OUO2NFQ9N2F-
MDCK NYLofG1CTnWwY4Tpc44h[XO|YYm= NUHoeYk3XFChVGLBUnNRV1KWRWK6JINmdGxiYXPjeY12dGG2aX;uJIlvKE:DVGC0R|Eu\XiycnXzd4lv\yCPRFPLJINmdGy|LDDLcV05|ryP NIWySoU9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9zNEm5N|YxPCd-MUS5PVM3ODR:L3G+
TK10 NWTq[FFsS3m2b4TvfIlkcXS7IHHzd4F6 MXq0PEBpenN? NGXZXXhEgXSxdH;4bYNqfHliYXfhbY5{fCCqdX3hckBVUzFyIHPlcIx{KGGodHXyJFQ5KGi{czDifUBUWkJiYYPzZZktKEmFNUC9NE4xOTR4zszN MkLwQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOTZ|MEmzNVUoRjF4M{C5N|E2RC:jPh?=
MCF7 NGXKSFlEgXSxdH;4bYNqfHliYYPzZZk> NFHBSZM1QCCqcoO= NXq0d4p6S3m2b4TvfIlkcXS7IHHnZYlve3RiaIXtZY4hVUOINzDj[YxteyCjZoTldkA1QCCqcoOgZpkhW1KEIHHzd4F6NCCLQ{WwQVAvODJ2Md88US=> NFTPbmk9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9zNkOwPVMyPSd-MU[zNFk{OTV:L3G+
K562 M4rLT2N6fG:2b4jpZ4l1gSCjc4PhfS=> MYDDfZRwfG:6aXPpeJkh[WejaX7zeEBpfW2jbjDLOVYzKGOnbHzzJIJ6KFiWVDDhd5NigSxiSVO1NF0xNjB{OENOwG0> NF\pNHY9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9zNkOwPVMyPSd-MU[zNFk{OTV:L3G+
UACC62 MXfDfZRwfG:6aXPpeJkh[XO|YYm= NUL2U4xnPDhiaILz NXPnRZB5S3m2b4TvfIlkcXS7IHHnZYlve3RiaIXtZY4hXUGFQ{[yJINmdGy|IHHmeIVzKDR6IHjyd{BjgSCVUlKgZZN{[XluIFnDOVA:OC5yMkm1{txO NFTXW|g9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9zNkOwPVMyPSd-MU[zNFk{OTV:L3G+
HeLa MnXvR5l1d3SxeHnjbZR6KGG|c3H5 NVe4PWU2S3m2b4TvfIlkcXS7IHHnZYlve3RiaIXtZY4hUGWOYTDj[YxteyCjc4Pld5Nm\CCjczDpcohq[mm2aX;uJI9nKESQQTDy[ZBtcWOjdHnvckBjgSCrbXHnbY5oKGGwYXz5d4l{ M33PcFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzF6ME[2NFU2Lz5zOEC2OlA2PTxxYU6=
HeLa MkW5SpVv[3Srb36gZZN{[Xl? M{TuVmlvcGmkaYTpc44hd2ZibXn0c5NqeyCrbjDoeY1idiCKZVzhJINmdGy|IHL5JIlu[WerbnegZY5idHm|aYO= MnW0QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOThyNk[wOVUoRjF6ME[2NFU2RC:jPh?=
colon cancer NFT3W2JEgXSxdH;4bYNqfHliYYPzZZk> MVm3NkBpenN? M{OzR2N6fG:2b4jpZ4l1gSCjZ3HpcpN1KGi3bXHuJINwdG:wIHPhcoNmeiClZXzsd{Bi\nSncjC3NkBpenNiYomgSm1ESSCvZYToc4QtKEmFNUC9NE4y|ryP MmPCQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOTl6OUS3N|MoRjF7OEm0O|M{RC:jPh?=
CC20 NX7iRllmS3m2b4TvfIlkcXS7IHHzd4F6 MWe3NkBpenN? MoS5R5l1d3SxeHnjbZR6KGGpYXnud5QhcHWvYX6gR2MzOCClZXzsd{Bi\nSncjC3NkBpenNiYomgSm1ESSCvZYToc4QtKEmFNUC9NE4zPM7:TR?= NFnFRm49[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9zOUi5OFc{Oyd-MUm4PVQ4OzN:L3G+
HCT116 M1GxXmN6fG:2b4jpZ4l1gSCjc4PhfS=> NVvNdnViPzJiaILz MmP1R5l1d3SxeHnjbZR6KGGpYXnud5QhcHWvYX6gTGNVOTF4IHPlcIx{KGGodHXyJFczKGi{czDifUBHVUODIH3leIhw\CxiSVO1NF0xNjJ5zszN MWe8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8yQTh7NEezN{c,OTl6OUS3N|M9N2F-
HT-29 M1XVTWN6fG:2b4jpZ4l1gSCjc4PhfS=> NUe2eXFNPzJiaILz MlH4R5l1d3SxeHnjbZR6KGGpYXnud5QhcHWvYX6gTHQuOjliY3XscJMh[W[2ZYKgO|IhcHK|IHL5JGZOS0FibXX0bI9lNCCLQ{WwQVEvPM7:TR?= M2\TWlxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzF7OEm0O|M{Lz5zOUi5OFc{OzxxYU6=
Hs578Bst MoW0R5l1d3SxeHnjbZR6KGG|c3H5 M3fOSVczKGi{cx?= M3fDPWN6fG:2b4jpZ4l1gSCjZ3HpcpN1KGi3bXHuJGh{PTd6QoP0JINmdGy|IHHmeIVzKDd{IHjyd{BjgSCFZXzsWIl1\XJvR3zvJIF{e2G7LDDJR|UxRTBwMEVOwG0> MUS8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zOjNzNkG2PEc,OjJ|MU[xOlg9N2F-
Hs578T MmjjR5l1d3SxeHnjbZR6KGG|c3H5 M2r3blczKGi{cx?= M2K3NGN6fG:2b4jpZ4l1gSCjZ3HpcpN1KGi3bXHuJGh{PTd6VDDj[YxteyCjZoTldkA4OiCqcoOgZpkhS2WubGTpeIVzNUeubzDhd5NigSxiSVO1NF0xNjJ3Md88US=> MXu8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zOjNzNkG2PEc,OjJ|MU[xOlg9N2F-
T47D NITVO5dEgXSxdH;4bYNqfHliYYPzZZk> M1HHRlczKGi{cx?= MV7DfZRwfG:6aXPpeJkh[WejaX7zeEBpfW2jbjDUOFdFKGOnbHzzJIFnfGW{IEeyJIhzeyCkeTDD[YxtXGm2ZYKtS4xwKGG|c3H5MEBKSzVyPUCuOlbPxE1? MV[8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zOjNzNkG2PEc,OjJ|MU[xOlg9N2F-
SK-BR-3 MUDDfZRwfG:6aXPpeJkh[XO|YYm= NHPNZ244OiCqcoO= Ml\uR5l1d3SxeHnjbZR6KGGpYXnud5QhcHWvYX6gV2suSlJvMzDj[YxteyCjZoTldkA4OiCqcoOgZpkhS2WubGTpeIVzNUeubzDhd5NigSxiSVO1NF0yNjB6zszN MnHIQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjJ|MU[xOlgoRjJ{M{G2NVY5RC:jPh?=
MCF7 NFnP[ohEgXSxdH;4bYNqfHliYYPzZZk> M4rXSFczKGi{cx?= NELUOJhEgXSxdH;4bYNqfHliYXfhbY5{fCCqdX3hckBOS0Z5IHPlcIx{KGGodHXyJFczKGi{czDifUBE\WyuVHn0[ZIuT2yxIHHzd4F6NCCLQ{WwQVQvP87:TR?= MkPtQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjJ|MU[xOlgoRjJ{M{G2NVY5RC:jPh?=
Hs578Bst M2\lZWN6fG:2b4jpZ4l1gSCjc4PhfS=> M2SwOFQxKHWP M1HMNlczKGi{cx?= NUK5TGxPS3m2b4TvfIlkcXS7IHHnZYlve3RiaIXtZY4hUHN3N{jCd5Qh[2WubIOgZZQhPDBidV2gZYZ1\XJiN{KgbJJ{KGK7IFPlcIxVcXSncj3HcI8h[XO|YYmgdoVt[XSrdnWgeI8hfW62cnXheIVlKGOxboTyc4wtKEmFNUC9OFcvP87:TR?= NVnnWoh1RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkKzNVYyPjhpPkKyN|E3OTZ6PD;hQi=>
CHO M3TtXmZ2dmO2aX;uJIF{e2G7 NXnsSYlkeEmFNUCgeoFtfWW|IH\vdkB{d2SrdX2g[ox2d3Knc3PlbY4hMDFyIIXNLUB2eHSja3WgbY4hV0GWUEHCNU11emGwc3\lZ5Rm\CCFSF:gZ4VtdHNuIFnDOVA:Oy5{M{W5OO69VQ>? NVjjemF4RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkO1O|E1OTVpPkKzOVcyPDF3PD;hQi=>
CHO MUHGeY5kfGmxbjDhd5NigQ>? NYD4UY9oeEmFNUCgeoFtfWW|IH\vdkB{d2SrdX2g[ox2d3Knc3PlbY4hMDFyIIXNLUB2eHSja3WgbY4hV0GWUEHCN{11emGwc3\lZ5Rm\CCFSF:gZ4VtdHNuIFnDOVA:OTNwMUiyOu69VQ>? M1LINlxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ|NUexOFE2Lz5{M{W3NVQyPTxxYU6=
Hs683 NGTNNJhEgXSxdH;4bYNqfHliYYPzZZk> MWGzJIRigXN? MlHNR5l1d3SxeHnjbZR6KGGpYXnud5QhcHWvYX6gTJM3QDNiY3XscJMh[W[2ZYKgN{Bl[Xm|IHL5JG1VXCCjc4PhfUwhUUN3ME2wMlA1|ryP Ml3pQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjN5ME[wNFUoRjJ|N{C2NFA2RC:jPh?=
A549 NGrqcHVEgXSxdH;4bYNqfHliYYPzZZk> MojPN{Bl[Xm| NGnJWIJEgXSxdH;4bYNqfHliYXfhbY5{fCCqdX3hckBCPTR7IHPlcIx{KGGodHXyJFMh\GG7czDifUBOXFRiYYPzZZktKEmFNUC9NE4xPc7:TR?= M2rNUlxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ|N{C2NFA2Lz5{M{ewOlAxPTxxYU6=
PC3 NULhNVBjS3m2b4TvfIlkcXS7IHHzd4F6 NYnTPG1GOyCmYYnz MkXaR5l1d3SxeHnjbZR6KGGpYXnud5QhcHWvYX6gVGM{KGOnbHzzJIFnfGW{IEOg[IF6eyCkeTDNWHQh[XO|YYmsJGlEPTB;MD6wO|XPxE1? MVi8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zOzdyNkCwOUc,OjN5ME[wNFU9N2F-
U373 M4PURWN6fG:2b4jpZ4l1gSCjc4PhfS=> NXn4VoxlOyCmYYnz MkTjR5l1d3SxeHnjbZR6KGGpYXnud5QhcHWvYX6gWVM4OyClZXzsd{Bi\nSncjCzJIRigXNiYomgUXRVKGG|c3H5MEBKSzVyPUCuNVQ3|ryP NEDPenk9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{M{ewOlAxPSd-MkO3NFYxODV:L3G+
SK-MEL-28 NUe3OXFJS3m2b4TvfIlkcXS7IHHzd4F6 NHLSeZc{KGSjeYO= M1f5Z2N6fG:2b4jpZ4l1gSCjZ3HpcpN1KGi3bXHuJHNMNU2HTD2yPEBk\WyuczDh[pRmeiB|IHThfZMh[nliTWTUJIF{e2G7LDDJR|UxRTBwMk[2{txO MYq8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zOzdyNkCwOUc,OjN5ME[wNFU9N2F-
MCF7 NYjMXHdzS3m2b4TvfIlkcXS7IHHzd4F6 NETMe2k{KGSjeYO= M2jjU2N6fG:2b4jpZ4l1gSCjZ3HpcpN1KGi3bXHuJG1ETjdiY3XscJMh[W[2ZYKgN{Bl[Xm|IHL5JG1VXCCjc4PhfUwhUUN3ME2wMlQzPs7:TR?= Ml\aQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjN5ME[wNFUoRjJ|N{C2NFA2RC:jPh?=
Drosophila Schneider cells MlHoSpVv[3Srb36gZZN{[Xl? NF;RUm9CdnSjZ3;ubZN1KGGldHn2bZR6KGG2IITyZY5{[WO2aY\heIlwdiCmb33hbY4hd2ZiUl;S[4FudWG2IDj1cotvd3ewIH;ybYdqdiliZYjwdoV{e2WmIHnuJGRzd3OxcHjpcIEhW2OqbnXp[IVzKGOnbHzzJINwNWW6cILld5NqdmdiR3HsOE1FVkFiYnnu[Ilv\yCmb33hbY4tKEmFNUC9Nu69VQ>? M1P1cFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ2MESwOFg3Lz5{NEC0NFQ5PjxxYU6=
Drosophila Schneider cells MYHGeY5kfGmxbjDhd5NigQ>? NEDlRlVCdnSjZ3;ubZN1KGGldHn2bZR6KGG2IITyZY5{[WO2aY\heIlwdiCmb33hbY4hd2ZiUl;S[4FudWG2IDj1cotvd3ewIH;ybYdqdiliZYjwdoV{e2WmIHnuJGRzd3OxcHjpcIEhW2OqbnXp[IVzKGOnbHzzJINwNWW6cILld5NqdmdiR3HsOE1FVkFiYnnu[Ilv\yCmb33hbY4tKEmFNUC9Nu69VQ>? MmnrQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjRyNEC0PFYoRjJ2MESwOFg3RC:jPh?=
RKO-AS45-1 NITJXW5EgXSxdH;4bYNqfHliYYPzZZk> NXK4bJoyPDhiaILz NF[0N5REgXSxdH;4bYNqfHliYXfhbY5{fCCqdX3hckBTU09vQWO0OU0yKGOnbHzzJIFnfGW{IES4JIhzeyCkeTDNWHQh[XO|YYmsJGlEPTB;MD60Nu69VQ>? M2nEd|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ4MUKyO|czLz5{NkGyNlc4OjxxYU6=
HeLa Ml\tR5l1d3SxeHnjbZR6KGG|c3H5 MoHJOFghcHK| NUfjN3BwS3m2b4TvfIlkcXS7IHHnZYlve3RiaIXtZY4hUGWOYTDj[YxteyCjZoTldkA1QCCqcoOgZpkhVVSWIHHzd4F6NCCLQ{WwQVIvOs7:TR?= NHracWM9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NkGyNlc4Oid-Mk[xNlI4PzJ:L3G+
HeLa NFzTZ5NHfW6ldHnvckBie3OjeR?= MYWxOVAhdk1? M2njblI1KGi{cx?= NVnOZppVUW6qaXLpeIlwdiCxZjDOZUgsMS:NKDupJGFVWGG|ZTDpckBpfW2jbjDI[WxiKGOnbHzzJIF1KDF3MDDuUUBi\nSncjCyOEBpenNiYomgbY1ufW6xYnzveJRqdmd? M{L4cFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ4MUKyO|czLz5{NkGyNlc4OjxxYU6=
HeLa MnX4SpVv[3Srb36gZZN{[Xl? MYKxOVAhdk1? NU\QSXR6OjRiaILz MWfJcohq[mm2aX;uJI9nKE6jKDupM2spMyliQWTQZZNmKGmwIHj1cYFvKEinTHGgZ4VtdHNiYYSgNVUxKG6PIHHmeIVzKDJ2IHjyd{BjgSCrbX31co9jdG:2dHnu[y=> MYq8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPjF{Mke3Nkc,OjZzMkK3O|I9N2F-
HeLa MWPGeY5kfGmxbjDhd5NigQ>? Mli1NVUxKG6P NWjiPGNVOjRiaILz NVnYNJlGUW6qaXLpeIlwdiCxZjDOZUgsMS:NKDupJGFVWGG|ZTDpckBpfW2jbjDI[WxiKGOnbHzzJIF1KDF3MDDuUUBi\nSncjCyOEBpenNiYomgbY1ufW6xYnzveJRqdmd? NIXKSFE9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NkGyNlc4Oid-Mk[xNlI4PzJ:L3G+
HeLa M4nsdmZ2dmO2aX;uJIF{e2G7 NWnpe2Y3OTVyIH7N MVuyOEBpenN? NIPvbIZKdmirYnn0bY9vKG:oIF7hLEsqN0tqKzmgRXRR[XOnIHnuJIh2dWGwIFjlUIEh[2WubIOgZZQhOTVyIH7NJIFnfGW{IEK0JIhzeyCkeTDpcY12dm:kbH;0eIlv\w>? Mk\oQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjZzMkK3O|IoRjJ4MUKyO|czRC:jPh?=
HeLa NUHtUYNkTnWwY4Tpc44h[XO|YYm= NHTqTXAyPTBibl2= NYCxfHhIOjRiaILz NX31cZR3UW6qaXLpeIlwdiCxZjDOZUgsMS:NKDupJGFVWGG|ZTDpckBpfW2jbjDI[WxiKGOnbHzzJIF1KDF3MDDuUUBi\nSncjCyOEBpenNiYomgbY1ufW6xYnzveJRqdmd? NVrWenlZRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMk[xNlI4PzJpPkK2NVIzPzd{PD;hQi=>
HeLa NVG1U3V{TnWwY4Tpc44h[XO|YYm= M1fBSFE2OCCwTR?= Ml70NlQhcHK| MVPJcohq[mm2aX;uJI9nKE6jKDupM2spMyliQWTQZZNmKGmwIHj1cYFvKEinTHGgZ4VtdHNiYYSgNVUxKG6PIHHmeIVzKDJ2IHjyd{BjgSCrbX31co9jdG:2dHnu[y=> MojFQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjZzMkK3O|IoRjJ4MUKyO|czRC:jPh?=
HeLa NXTrSYdSTnWwY4Tpc44h[XO|YYm= MnL0NVUxKG6P M1zSRVI1KGi{cx?= MVPJcohq[mm2aX;uJI9nKE6jKDupM2spMyliQWTQZZNmKGmwIHj1cYFvKEinTHGgZ4VtdHNiYYSgNVUxKG6PIHHmeIVzKDJ2IHjyd{BjgSCrbX31co9jdG:2dHnu[y=> NEnyUFk9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NkGyNlc4Oid-Mk[xNlI4PzJ:L3G+
HeLa MljXSpVv[3Srb36gZZN{[Xl? MYWxOVAhdk1? M4j1XlI1KGi{cx?= MoP2TY5pcWKrdHnvckBw\iCQYTirLU9MMCtrIFHUVIF{\SCrbjDoeY1idiCKZVzhJINmdGy|IHH0JFE2OCCwTTDh[pRmeiB{NDDodpMh[nliaX3teY5w[myxdITpcoc> NFvuWI09[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NkGyNlc4Oid-Mk[xNlI4PzJ:L3G+
Kasumi-1 NF\KWGtEgXSxdH;4bYNqfHliYYPzZZk> NGC4No41QCCqcoO= NYfJc5F{S3m2b4TvfIlkcXS7IHHnZYlve3RiaIXtZY4hU2G|dX3pMVEh[2WubIOgbY5kfWKjdHXkJIZweiB2ODDodpMh[nliTWTTJIF{e2G7LDDJR|UxRTBwMEmz{txO NFH3OZY9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{N{m4N|g1Oid-Mke5PFM5PDJ:L3G+
MV4-11 MkDKR5l1d3SxeHnjbZR6KGG|c3H5 MYe0PEBpenN? NInLPIlEgXSxdH;4bYNqfHliYXfhbY5{fCCqdX3hckBOXjRvMUGgZ4VtdHNiaX7jeYJifGWmIH\vdkA1QCCqcoOgZpkhVVSVIHHzd4F6NCCLQ{WwQVAvOTFzzszN M4f2bVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ5OUizPFQzLz5{N{m4N|g1OjxxYU6=
HT-29 NV;TXmt6S3m2b4TvfIlkcXS7IHHzd4F6 NFrDRmM4OiCqcoO= NFuzXmpEgXSxdH;4bYNqfHliYXfhbY5{fCCqdX3hckBJXC1{OTDj[YxteyCrbnP1ZoF1\WRiZn;yJFczKGi{czDifUBUWkJiYYPzZZktKEmFNUC9NE4{QM7:TR?= MofpQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjd7OEO4OFIoRjJ5OUizPFQzRC:jPh?=
H1299 Mme5R5l1d3SxeHnjbZR6KGG|c3H5 NIr6d2UzPCCqcoO= M2nnSGN6fG:2b4jpZ4l1gSCjZ3HpcpN1KGi3bXHuJGgyOjl7IHPlcIx{KGmwY4XiZZRm\CCob4KgNlQhcHK|IHL5JG1VXCCjc4PhfUwhUUN3ME2wMlQ3|ryP Mn3zQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjd7OEO4OFIoRjJ5OUizPFQzRC:jPh?=
CCD-112CoN MYrDfZRwfG:6aXPpeJkh[XO|YYm= MlnGO|IhcHK| M3jrcGN6fG:2b4jpZ4l1gSCjZ3HpcpN1KGi3bXHuJGNETC1zMULDc24h[2WubIOgbY5kfWKjdHXkJIZweiB5MjDodpMtKEmFNUC9Nk41|ryP NXzIbnF5RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMke5PFM5PDJpPkK3PVg{QDR{PD;hQi=>
DU145 M4PN[WZ2dmO2aX;uJIF{e2G7 MlvFOVAhfU1? M1vO[VUhcHK| M17VcWlvcGmkaYTpc44hd2ZiTnGrM2ssKEGWUHHz[UBxfW2yIHnuJIh2dWGwIFTVNVQ2KGOnbHzzJIF{e2W|c3XkJIF{KGmwY4LlZZNmKGmwIHnueJJi[2WubIXsZZIh[2GuY3n1cUBt\X[nbDDheEA2OCC3TTDt[YF{fXKnZDDh[pRmeiB3IHjyd{BjgSCIdYLhMVIwSU1iZInlJIJie2WmIH\seY9z\XOlZX7j[UBie3OjeR?= NXThUoc2RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxM{GxNlAzPTFpPkOxNVIxOjVzPD;hQi=>
DU145 MVTGeY5kfGmxbjDhd5NigQ>? NH7YbGQ2OCC3TR?= NFe2RVA2KGi{cx?= MkezTY5pcWKrdHnvckBw\iCQYTuvT{shSVSSYYPlJJB2dXBiaX6gbJVu[W5iRGWxOFUh[2WubIOgZZN{\XO|ZXSgZZMhcW6lcnXhd4UhcW5iaX70doFk\WyudXzhdkBk[WylaYXtJIxmfmWuIHH0JFUxKHWPIH3lZZN2emWmIHHmeIVzKDViaILzJIJ6KE[3cnGtNk9CVSCmeXWgZoF{\WRiZnz1c5Jme2OnbnPlJIF{e2G7 NIjocFM9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9|MUGyNFI2OSd-M{GxNlAzPTF:L3G+
DU145 MkPKSpVv[3Srb36gZZN{[Xl? NUfxd484PTBidV2= NIm4UFI2KGi{cx?= MoTLTY5pcWKrdHnvckBw\iCQYTuvT{shSVSSYYPlJJB2dXBiaX6gbJVu[W5iRGWxOFUh[2WubIOgZZN{\XO|ZXSgZZMhcW6lcnXhd4UhcW5iaX70doFk\WyudXzhdkBk[WylaYXtJIxmfmWuIHH0JFUxKHWPIH3lZZN2emWmIHHmeIVzKDViaILzJIJ6KE[3cnGtNk9CVSCmeXWgZoF{\WRiZnz1c5Jme2OnbnPlJIF{e2G7 NYHkc2V1RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxM{GxNlAzPTFpPkOxNVIxOjVzPD;hQi=>
DU145 MkLuSpVv[3Srb36gZZN{[Xl? MVe1NEB2VQ>? Ml73OUBpenN? MX;Jcohq[mm2aX;uJI9nKE6jKz;LL{BCXFCjc3WgdJVueCCrbjDoeY1idiCGVUG0OUBk\WyuczDhd5Nme3OnZDDhd{BqdmO{ZXHz[UBqdiCrboTyZYNmdGy3bHHyJINidGOrdX2gcIV3\WxiYYSgOVAhfU1ibXXhd5Vz\WRiYX\0[ZIhPSCqcoOgZpkhTnW{YT2yM2FOKGS7ZTDiZZNm\CCobIXvdoV{[2WwY3WgZZN{[Xl? MWW8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8{OTF{MEK1NUc,OzFzMkCyOVE9N2F-
DU145 NGO5e3pHfW6ldHnvckBie3OjeR?= Mn;WOVAhfU1? NIrGepk2KGi{cx?= MknYTY5pcWKrdHnvckBw\iCQYTuvT{shSVSSYYPlJJB2dXBiaX6gbJVu[W5iRGWxOFUh[2WubIOgZZN{\XO|ZXSgZZMhcW6lcnXhd4UhcW5iaX70doFk\WyudXzhdkBk[WylaYXtJIxmfmWuIHH0JFUxKHWPIH3lZZN2emWmIHHmeIVzKDViaILzJIJ6KE[3cnGtNk9CVSCmeXWgZoF{\WRiZnz1c5Jme2OnbnPlJIF{e2G7 MlOzQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOzFzMkCyOVEoRjNzMUKwNlUyRC:jPh?=
DU145 NIHyT5FHfW6ldHnvckBie3OjeR?= MVi1NEB2VQ>? NUfP[IV1PSCqcoO= NGnzXnNKdmirYnn0bY9vKG:oIF7hL{9MMyCDVGDhd4UheHWvcDDpckBpfW2jbjDEWVE1PSClZXzsd{Bie3Onc4Pl[EBieyCrbnPy[YF{\SCrbjDpcpRz[WOnbHz1cIFzKGOjbHPpeY0hdGW4ZXygZZQhPTBidV2gcYVie3W{ZXSgZYZ1\XJiNTDodpMh[nliRoXyZU0zN0GPIHT5[UBj[XOnZDDmcJVwemW|Y3XuZ4Uh[XO|YYm= MkjsQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOzFzMkCyOVEoRjNzMUKwNlUyRC:jPh?=
DU145 MXXGeY5kfGmxbjDhd5NigQ>? NX;RXJFuPTBidV2= NYrQWIQ5PSCqcoO= MYHJcohq[mm2aX;uJI9nKE6jKz;LL{BCXFCjc3WgdJVueCCrbjDoeY1idiCGVUG0OUBk\WyuczDhd5Nme3OnZDDhd{BqdmO{ZXHz[UBqdiCrboTyZYNmdGy3bHHyJINidGOrdX2gcIV3\WxiYYSgOVAhfU1ibXXhd5Vz\WRiYX\0[ZIhPSCqcoOgZpkhTnW{YT2yM2FOKGS7ZTDiZZNm\CCobIXvdoV{[2WwY3WgZZN{[Xl? MmLhQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOzFzMkCyOVEoRjNzMUKwNlUyRC:jPh?=
DU145 MX\GeY5kfGmxbjDhd5NigQ>? NEXZc3o2OCC3TR?= MXe1JIhzew>? MVnJcohq[mm2aX;uJI9nKE6jKz;LL{BCXFCjc3WgdJVueCCrbjDoeY1idiCGVUG0OUBk\WyuczDhd5Nme3OnZDDhd{BqdmO{ZXHz[UBqdiCrboTyZYNmdGy3bHHyJINidGOrdX2gcIV3\WxiYYSgOVAhfU1ibXXhd5Vz\WRiYX\0[ZIhPSCqcoOgZpkhTnW{YT2yM2FOKGS7ZTDiZZNm\CCobIXvdoV{[2WwY3WgZZN{[Xl? NXjxSYJXRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxM{GxNlAzPTFpPkOxNVIxOjVzPD;hQi=>
Assay
Methods Test Index PMID
Western blot p-Src / Src / p-EGFR / EGFR / p-STAT3 / STAT3 ; p-PI3K / PI3K / p-AKT / AKT / p-MEK / MEK / p-ERK / ERK / p-FAK / FAK / p-SAPK/JNK / p-Paxillin / Paxillin / p-p130Cas / p130Cas ; Nrf2 25955608 30735911
Growth inhibition assay Cell viability 25955608

Protocol (from reference)

Solubility (25°C)

In vitro

DMSO 100 mg/mL
(128.05 mM)
Water Insoluble
Ethanol Insoluble

In vivo

Add solvents to the product individually and in order
(Data is from Selleck tests instead of citations):
2% DMSO+corn oil
For best results, use promptly after mixing.

2mg/mL

* Please note that Selleck tests the solubility of all compounds in-house, and the actual solubility may differ slightly from published values. This is normal and is due to slight batch-to-batch variations.

Chemical Information

Molecular Weight 780.94
Formula

C41H64O14

CAS No. 20830-75-5
Storage 3 years -20°C powder
2 years -80°C in solvent
Smiles CC1C(C(CC(O1)OC2C(OC(CC2O)OC3C(OC(CC3O)OC4CCC5(C(C4)CCC6C5CC(C7(C6(CCC7C8=CC(=O)OC8)O)C)O)C)C)C)O)O

In vivo Formulation Calculator (Clear solution)

Step 1: Enter information below (Recommended: An additional animal making an allowance for loss during the experiment)

mg/kg g μL

Step 2: Enter the in vivo formulation (This is only the calculator, not formulation. Please contact us first if there is no in vivo formulation at the solubility Section.)

% DMSO % % Tween 80 % ddH2O
%DMSO %

Calculation results:

Working concentration: mg/ml;

Method for preparing DMSO master liquid: mg drug pre-dissolved in μL DMSO ( Master liquid concentration mg/mL, Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug. )

Method for preparing in vivo formulation: Take μL DMSO master liquid, next addμL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O, mix and clarify.

Method for preparing in vivo formulation: Take μL DMSO master liquid, next add μL Corn oil, mix and clarify.

Note: 1. Please make sure the liquid is clear before adding the next solvent.
2. Be sure to add the solvent(s) in order. You must ensure that the solution obtained, in the previous addition, is a clear solution before proceeding to add the next solvent. Physical methods such
as vortex, ultrasound or hot water bath can be used to aid dissolving.

Molarity Calculator

Mass Concentration Volume Molecular Weight

Clinical Trial Information

NCT Number Recruitment Interventions Conditions Sponsor/Collaborators Start Date Phases
NCT05137626 Not yet recruiting Drug: AT-527 + digoxin Healthy Volunteers Study Atea Pharmaceuticals Inc.|Hoffmann-La Roche November 2021 Phase 1
NCT05014087 Recruiting Drug: Intravenous digoxin Acute Alcoholic Hepatitis|Chemical and Drug Induced Liver Injury|Alcohol-Induced Disorders|Steatohepatitis Caused by Ingestible Alcohol Yale University October 8 2021 Phase 2
NCT03559868 Recruiting Drug: Digoxin|Other: Placebo Inflammatory Response Yale University March 1 2021 Phase 1

(data from https://clinicaltrials.gov, updated on 2022-01-17)

Tech Support

Answers to questions you may have can be found in the inhibitor handling instructions. Topics include how to prepare stock solutions, how to store inhibitors, and issues that need special attention for cell-based assays and animal experiments.

Handling Instructions

Tel: +1-832-582-8158 Ext:3
If you have any other enquiries, please leave a message.

* Indicates a Required Field

Please enter your name.
Please enter your email. Please enter a valid email address.
Please write something to us.
Tags: buy Digoxin (NSC 95100) | Digoxin (NSC 95100) supplier | purchase Digoxin (NSC 95100) | Digoxin (NSC 95100) cost | Digoxin (NSC 95100) manufacturer | order Digoxin (NSC 95100) | Digoxin (NSC 95100) distributor